Drug efflux transporters and antiviral drug therapy

Expert Opinion on Therapeutic Targets

Volumn 4, Issue 4, 2000, Pages 439-446

  Kim, Richard B ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antiviral; drug interaction; drug transporters; HIV; pharmacokinetics

Indexed keywords

EID: 80051997993     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.4.4.439     Document Type: Review

References (48)

1. KOLSON DL, LAVIE, GONZALEZ-SCARANO F: The effects of human immunodeficiency virus in the central nervous system. Adv.Virus Res. (1998) 50:1-47.
2. ZHANG H, DORNADULA G, BEUMONT M et al: Human immunodeficiency virus Type 1 in the semen of men receiving highly active antiretroviral therapy. N. Engl. J. Med. (1998) 339:1803-1809.
3. THIEBAUT F, TSURUO T, HAMADA H, GOTTESMAN MM, PASTAN I, WILLINGHAM MC: Cellular localisation of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA (1987) 84:7735-7738.
4. CORDON-CARDO C, O'BRIEN JP, CASALS D et al.: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA (1989) 86:695-698.
5. Methods in Enzymology-ABC Transporters: Biochemical, Cellular and Molecular Aspects (volume 292), Ambudkar SV, Gottesman MM (Eds.), Academic Press, London, UK (1998).
6. KLEIN I, SARKADI B, VARADI A: An inventory of the human ABC proteins. Biochim. Biophys. Acta (1999) 1461:237-262.
7. AMBUDKAR SV, DEY S, HRYCYNA CA, RAMACHANDRA M, PASTAN I, GOTTESMAN MM: Biochemical, cellular and pharmacological aspects of the multidrug transporter. Ann. Rev. Pharmacol. Toxicol. (1999) 39:361-398.
8. GOTTESMAN MM, HRYCYNA CA, SCHOENLEIN PV, GERMANN UA, PASTAN I: Genetic analysis of the multidrug transporter. Ann. Rev. Genetics (1995) 29:607-649.
9. BELLAMY WT: P-glycoproteins and multidrug resistance. Ann. Rev. Pharmacol. Toxicol. (1996) 36:161-183.
10. SCHINKEL AH, SMIT JJM, VAN TELLINGEN O et al.: Disrup tion of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell (1994) 77:491-502.
11. UMBENHAUER DR, LANKAS GR, PIPPERT TR et al: Identi fication of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol. App. Pharmacol. (1997) 146:88-94.
12. SCHINKEL AH, MAYER U, WAGENAAR E et al: Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl. Acad. Sci. USA (1997) 94:4028-4033.
13. SCHINKEL AH, WAGENAAR E, VAN DEEMTER L, MOL CAAM, BORST P: Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J. Clin. Invest. (1995) 96:1698-1705.
14. SCHINKEL AH, MOL CAAM, WAGENAAR E, VAN DEEMTER L, SMIT JJM, BORST P: Multidrug resistance and the role of P-glycoprotein knockout mice. Eur. J. Cancer (1995) 31A:1295-1298.
15. KWEI GY, ALVARO RF, CHEN Q et al: Disposition of ivermectin and cyclosporin Ain CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab. Dispos. (1999) 27:581-587.
16. KIM RB, FROMM MF, WANDEL C et al.: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest (1998) 101:289-294.
17. SCHINKEL AH, WAGENAAR E, MOL CA, VAN DEEMTER L: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. (1996) 97:2517-2524.
18. LANKAS GR, WISE LD, CARTWRIGHT ME, PIPPERT T, UMBENHAUER DR: Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod. Toxicol. (1998) 12:457-463.
19. SMIT JW, HUISMAN MT, VAN TELLINGEN O, WILTSHIRE HR, SCHINKEL AH: Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin. Invest. (1999) 104:1441-1447.
20. WACHER VJ, WU C-Y, BENET LZ: Overlapping substrate specificities and tissue distribution of cytochrome P450 3a and p-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinogen. (1995) 13:129-134.
21. KIM RB, WANDEL C, LEAKE B et al: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. (1999) 16:408-414.
22. SCHUETZ EG, BECK WT, SCHUETZ JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. (1996) 49:311-318.
23. VAN HELVOORT A, SMITH AJ, SPRONG H et al.,: MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell (1996) 87:507-517.
24. SMIT JJ, SCHINKEL AH, OUDE ELFERINK RPJ et al.: Homozygous disrupting of the murine mdr2 p-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell (1993) 75:451-462.
25. TRAUNER M, MEIER PJ, BOYER JL: Molecular regulation of hepatocellular transport systems in cholestasis. J. Hepatol. (1999) 31:165-178.
26. STRAUTNIEKS SS, BULL LN, KNISELY AS et al.: A gene encodingaliver- specific ABCtransporterismutatedin progressive familial intrahepatic cholestasis. Nature Genet. (1998) 20:233-238.
27. COLE SPC, BHARDWAJ G, GERLACH J et al.: Overexpres-sion of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (1992) 258:1650-1654.
28. KONIG J, NIES AT, CUI Y, LEIER I, KEPPLER D: Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity and MRP2-mediated drug resistance. Biochim. Biophys. Acta (1999) 1461:377-394.
29. HIPFNER DR, DEELEY RG, COLE SP: Structural, mechanistic and clinical aspects of MRP1. Biochim. Biophys. Acta (1999) 1461:359-376.
30. RAO VV, DAHLHEIMER JL, BARDGETT ME et al.: Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier [in process citation]. Proc. Natl. Acad. Sci. USA (1999) 96:3900-3905.
31. WIJNHOLDS J, DELANGE EC, SCHEFFER GL et al.: Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J. Clin. Invest (2000) 105:279-285.
32. WIJNHOLDS J, SCHEFFER GL, VAN d, V, BEIJNEN JH, SCHEPER RJ, BORST P: Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. J. Exp. Med. (1998) 188 :797-808.
33. WIJNHOLDS J, EVERS R, VANLEUSDEN MR et al.: Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nature Med. (1997) 3:1275-1279.
34. KARTENBECK J, LEUSCHNER U, MAYER R, KEPPLER D: Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology (1996) 23:1061-1066.
35. WADA M, TOH S, TANIGUCHI K et al.: Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum. Mol. Genet. (1998) 7:203-207.
36. KAJIHARA S, HISATOMI A, MIZUTA T et al: A splice mutation in the human canalicular multispecific organic anion transporter gene causes Dubin-Johnson syndrome. Biochem. Biophys. Res. Commun. (1998) 253:454-457.
37. PAULUSMA CC, BOSMA PJ, ZAMAN GJR et al: Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science (1996) 271:1126-1128.
38. BORST P, EVERS R, KOOL M, WIJNHOLDS J: The multidrug resistance protein family. Biochim. Biophys. Acta (1999) 1461:347-357.
39. FROMM MF, LEAKE B, RODEN DM, WILKINSON GR, KIM RB: Human MRP3 transporter: identification of the 5'-flanking region, genomic organization and alternative splice variants. Biochim. Biophys. Acta (1999) 1415:369-374.
40. SCHUETZ JD, CONNELLY MC, SUN D et al.: MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nature Med. (1999) 5:1048-1051.
41. GROOTHUIS DR, LEVY RM: The entry of antiviral and antiretroviral drugs into the central nervous system. J. Neurovirol. (1997) 3:387-400.
42. LEE CG, GOTTESMAN MM, CARDARELLI CO et al.: HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry (1998) 37:3594-3601.
43. KIM AE, DINTAMAN JM, WADDELL DS, SILVERMAN JA: Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J. Pharmacol. Exp. Ther. (1998) 286:1439-1445.
44. CHOO EF, LEAKE B, WANDEL C et al.: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. DrugMetab. Dispos. (2000) 28:655-660.
45. FERRY DR: Testing the role of P-glycoprotein expression in clinical trials-applying pharmacological principles and best methods for detection together with good clinical trials methodology. Int. J. Clin. Pharmacol. Ther. (1998) 36:29-40.
46. THUMMEL KE, WILKINSON GR: In vitroand in vivodrug interactions involving human CYP3A. Ann. Rev. Pharmacol. Toxicol. (1998) 38:389-430.
47. PAUL AJ, TRANQUILLI WJ, SEWARD RL, TODD KSJ, DIPIETRO JA: Clinical observations in collies given ivermectin orally. Am. J. Vet. Res. (1987) 48:684-685.
48. HOFFMEYER S, BURK O, VON RICHTER O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA (2000) 97:3473-3478.